This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
HenzeT, RieckmannP, ToykaKV; Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78–105.
3.
LedinekAH, SajkoMC, RotU. Evaluating the effects of amantadine, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis – result of a pilot randomized, blind study. Clin Neurol Neurosurg. 2013;115(Suppl 1):S86–89.
4.
ShaygannejadV, JanghorbaniM, AshtariF, ZakeriH. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: A randomized, blinded, crossover study. Neurol Res. 2012;34(9): 854–858.
5.
PucciE, BranãsP, D'AmicoR, GiulianiG, SolariA, TausC. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;1:CD002818.
6.
PayneC, WiffenPJ, MartinS. Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database Syst Rev. 2012;1:CD008427.
